In this article, we will look at 11 Oversold NASDAQ Stocks to Buy Right Now.
On April 28, Darrell Cronk, Wells Fargo Wealth and Investment Management CIO, appeared on CNBC’s ‘Squawk on the Street’ to discuss market outlooks and what investors should look at in the current market circumstances. He opined that it is growth that investors should be worried about, not inflation. Cronk was of the view that the market will likely see better buying/entry opportunities in the coming weeks, and so it is essential to be careful when chasing equities too hard. There is a growing divide between sentiment and positioning, as we live in a geopolitical-first world where the rules of the game can change with stunning speed.
Cronk further opined that many people overlook a key fact about tariffs, solely focusing on their inflationary nature. While tariffs are inflationary, they are blunt-force resets in prices and are not sustained inflationary. So, although companies need to be able to absorb the blunt force reset of prices and impact of margins, it’s not like one continues to see the rate of change of inflation move meaningfully higher up from years one to two, three, and four. This trend only emerges when tariffs move meaningfully higher up over a period of time.
READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 10 Best Stocks That Will Always Grow.
Are Rate Cuts a Good Idea?
Cronk also talked about how the president has been screaming at the Fed to slash interest rates. But it’s not just the president; the bond market is doing the same. Fed cuts over a period of time are essential. However, according to Cronk, if the Fed shows up tomorrow and announces an emergency cut of sorts, markets wouldn’t perceive it so well. The markets would take it as the Fed knowing something they do not, and the growth scare would grow more pervasive and problematic. This is why the Fed has to be careful about how they act.
The Fed appears to be more concerned about inflation, and it has been consistent in that. If they switched to more growth concerns than inflation concerns, the markets would perceive them as more dovish. He said that we just saw the Fed’s president saying that June could be on the table for a possible rate cut. The Fed is thus starting to lay the groundwork, and we would have to see how that narrative turns out. If it takes a more dovish approach, markets would perceive that in a well-timed, thoughtful way.
Since April 1, nine of the eleven S&P gig sectors have revised their guidance lower. The problem is that out of the 20%- 25% of the reported earnings that the market has seen right now, less than 20% of them have been willing to give forward guidance. Therefore, Cronk highlighted that the guidance suspension is obviously problematic and important here. The market thus needs consumer discretionary stocks and industrials to hold up and tech to deliver.
With these trends in view, let’s look at the 11 oversold NASDAQ stocks to buy right now.
10 stocks receiving a massive vote of approval from Wall Street analysts
Our Methodology
We used stock screeners to compile a list of NASDAQ stocks that experienced significant YTD performance declines. We then selected the 11 stocks with the highest analyst upside potential as of April 29, 2025. We also added the number of hedge fund holders for these stocks as of Q4 2024, sourcing hedge fund data from Insider Monkey’s database. The list is sorted in ascending order of the upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (see more details here).
11 Oversold NASDAQ Stocks to Buy Right Now
11. Agilysys, Inc. (NASDAQ:AGYS)
Perf YTD: -43.91%
Analyst Upside: 48.89%
Number of Hedge Fund Holders: 20
Agilysys, Inc. (NASDAQ:AGYS) provides hospitality software delivering cloud-native software-as-a-service (SaaS) and on-premises solutions for cruise lines and other sectors, including hotels, resorts, restaurants, stadiums, corporate food service management, and more. The company offers innovative software for various purposes, including inventory and procurement, document management, payment gateway, reservation and table management, and more. It also serves the gaming industry for cruise lines and other sectors, and ranks 11th on our list of the top oversold NASDAQ stocks to buy right now.
Analysts have bullish sentiments for the stock. On April 28, Craig-Hallum analyst George Sutton maintained a Buy rating on Agilysys, Inc. (NASDAQ:AGYS). Oppenheimer analyst Brian Schwartz also maintained a Buy rating on the company on April 9, setting a $90.00 price target.
In addition, Needham analyst Mayank Tandon reiterated a Buy rating on Agilysys, Inc. (NASDAQ:AGYS) on March 5, setting a price target of $100.00 and saying it has a positive outlook. The analyst told investors in a research note that the company has the potential to overcome current headwinds in its point-of-sale sales and services revenue, which they consider to be temporary headwinds. The analyst expects growth to rebound to its usual trends within two to three quarters.
The firm provided various other reasons to support their bullish stance on the stock, saying that Agilysys, Inc. (NASDAQ:AGYS) is well-positioned in the considerable $16 billion total addressable market with leading products in point-of-sale solutions and property management systems for the hospitality sector. It has also bolstered its sales leadership team, which the analyst expects will support over a 25% sustained organic subscription revenue growth rate per annum and expanding EBITDA margins.
10. Rigetti Computing, Inc. (NASDAQ:RGTI)
Perf YTD: -39.58%
Analyst Upside: 62.69%
Number of Hedge Fund Holders: 17
Rigetti Computing, Inc. (NASDAQ:RGTI) provides full-stack computing services to the government, global enterprises, and research clients through its Rigetti Quantum Cloud Services platform. The company manufactures and designs its own quantum processing units (QPUs) and builds entire quantum computing systems. Its superconducting qubits employ existing semiconductor processes, a commonly used and more tried and tested technique compared to its rivals.
Analysts are bullish on the stock, even when Rigetti Computing, Inc. (NASDAQ:RGTI) doesn’t generate much revenue yet. Analysts regard it as investing in Nvidia before the AI boom began in the 2010s, as quantum computing is expected to become a force to reckon with in the future. Since Rigetti Computing, Inc. (NASDAQ:RGTI) conducts the complete process of manufacturing a quantum computer itself, going from chip design and software to manufacturing and operating the system, it is a one-stop shop for the current quantum technology. The company’s largest customers include the Horizon Quantum Computing in Singapore, the Air Force Research Lab, and the Superconducting Quantum Materials and Systems Center.
It delivered $11 million in revenue in 2024, but analysts estimate revenue to rise to $14 million in 2025, with net loss dropping to $70 million. Rigetti Computing, Inc. (NASDAQ:RGTI) plans to launch a non-modular 100-qubit system in 2026, aiming to continue this trajectory and manufacture an even more powerful 336-qubit system in the coming years. The company also plans to improve its median gate fidelity, which means the rate at which it identifies errors, to 99.5% in its future systems from 99% today. On April 23, Craig-Hallum analyst Richard Shannon maintained a Buy rating on Rigetti Computing, Inc. (NASDAQ:RGTI).
9. Freshpet, Inc. (NASDAQ:FRPT)
Perf YTD: -50.44%
Analyst Upside: 63.49%
Number of Hedge Fund Holders: 40
Freshpet, Inc. (NASDAQ:FRPT) ranks ninth on our list of oversold NASDAQ stocks to invest in now. The company manufactures, markets, and distributes packaged pet food and treats. Its products include a blend of locally farmed vegetables, fresh meat, and fruits. The company’s products include Deli Fresh Grain Free Chicken Recipe for Dogs, Ocean Whitefish Recipe for Cats, Joy Turkey and Apple Bites Treats, Nature’s Fresh Grain Free Chicken Recipe for Cats, and more.
On April 10, Benchmark Co. analyst Todd Brooks maintained their bullish stance on Freshpet, Inc. (NASDAQ:FRPT) and gave the stock a buy rating. Even though the analyst reduced the stock’s price target to $140, he said the company’s current and future performance and strong market position in the fresh dog food segment support the Buy rating. These factors are expected to help it attain significant AEBITDA growth by fiscal year 2027. The analyst opined that Freshpet, Inc. (NASDAQ:FRPT) currently holds a modest 3% share in the $37 billion US dog food market, which gives it a competitive advantage.
He also noted that while the company has some short-term challenges, such as macroeconomic pressures affecting consumer confidence and disruptions in the Pet Specialty channel, they will likely be temporary. Freshpet, Inc. (NASDAQ:FRPT) has low exposure to tariff-related expenses, and it is exhibiting a historically strong correlation between advertising and growing website traffic, which the analyst sees as positive indicators of future growth. In another report released on April 10, Stifel Nicolaus maintained a Buy rating on Freshpet, Inc. (NASDAQ:FRPT) and set a $115.00 price target.
8. Marvell Technology, Inc. (NASDAQ:MRVL)
Perf YTD: -46.85%
Analyst Upside: 70.36%
Number of Hedge Fund Holders: 105
Marvell Technology, Inc. (NASDAQ:MRVL) designs, develops, and sells integrated circuits. The company’s offerings include security solutions, data processing units, ethernet controllers, automotive, ethernet switches, ASICs, and more. Headquartered in Wilmington, Delaware, its operations are divided into the following geographical segments: the United States, Singapore, Israel, India, China, and Others.
Although 2025 has been a challenging year for Marvell Technology, Inc. (NASDAQ:MRVL) so far, analysts believe that the company’s specialism in AI silicon, amongst other technologies, and a strong work pipeline could support long-term growth. The company reported a notable revenue of $5.8 billion in fiscal year 2025. Its data center segment underwent a 78% year-over-year growth, reporting a record $1.37 billion in revenue in fiscal Q4 2025. This growth was attributed to strong AI demand and custom silicon programs.
Analysts are thus bullish on the stock as AI demand is expected to continue growing consistently in the future. The company expects to exceed its AI revenue target of $2.5 billion in fiscal year 2026 and is the eighth-best oversold NASDAQ stock to buy now. In a report released on April 22, Thomas O’Malley from Barclays maintained a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) and set a price target of $80.00.
7. Astera Labs, Inc. (NASDAQ:ALAB)
Perf YTD: -50.11%
Analyst Upside: 77.06%
Number of Hedge Fund Holders: 51
Astera Labs, Inc. (NASDAQ:ALAB) is a global semiconductor company that provides software and hardware solutions for AI and cloud infrastructure applications to solve memory, data, and networking bottlenecks. The company’s operations are divided into the following geographical segments: Taiwan, China, the United States, and Other.
In a report released on April 22, Thomas O’Malley from Barclays maintained a Buy rating on Astera Labs, Inc. (NASDAQ:ALAB) and set a price target of $70.00. The company has solid operations. It reported a record quarterly revenue of $141.1 million in fiscal Q4 2024, reflecting a 25% quarter-over-quarter and 179% year-over-year growth. It also reported record fiscal 2024 revenue of $396.3 million, up a notable 242% compared to last year. The strong revenue growth was attributed to the company’s Aries PCIe Retimer products, with Taurus Smart Cable Modules for Ethernet also performing solidly in fiscal Q4 2024.
Astera Labs, Inc. (NASDAQ:ALAB) expects 2025 to be a breakout year for the company, which is why analysts are bullish on the stock and it ranks seventh on our list of oversold NASDAQ stocks to invest in right now. The company is accelerating its operations across diverse platforms and customers with four product families. This includes its backend AI accelerator scale-up clustering and flagship Scorpio Fabric products for head-node PCIe connectivity.
6. Acadia Healthcare Company, Inc. (NASDAQ:ACHC)
Perf YTD: -44.06%
Analyst Upside: 80.34%
Number of Hedge Fund Holders: 46
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US in various settings, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics.
Guggenheim analyst Jason Cassorla initiated coverage of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) with a Buy rating and $36 price target on April 9, reasoning that investors are looking for value in the managed care, hospitals, and behavioral health sector, or stocks with compelling stories “outside the noise.”
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) has positive operations, as it reported a revenue of $774.2 million in fiscal Q4 2024, up 4.2% over fiscal Q4 2023. Same facility revenue also rose 4.7% compared to the same quarter last year, including a 1.4% growth in revenue per patient day and a 3.2% rise in patient days. The company also added 577 newly licensed beds in the quarter, which included 344 licensed beds from newly constructed facilities and 233 beds from existing facilities. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is continually expanding its operations, completing construction on around 1,100 beds in fiscal Q4 2024 and bringing the full-year count to around 1,300 newly constructed beds.
5. Weatherford International plc (NASDAQ:WFRD)
Perf YTD: -41.20%
Analyst Upside: 82.81%
Number of Hedge Fund Holders: 36
Weatherford International plc (NASDAQ:WFRD) provides services and equipment to the natural gas and oil exploration and production industry. The company has operations in the Drilling and Evaluation (DRE), Well Construction and Completions (WCC), and Production and Intervention (PRI) segments. The WCC segment includes liner hangers, tubular running services, cementation products, well services, and completions, while the DRE segment offers drilling services, drilling fluids, wireline, and managed pressure drilling. The company’s PRI segment manages pressure pumping services, production automation and software, artificial life, sub-sea intervention, and more.
On April 23, analyst James Rollyson from Raymond James maintained a Buy rating on Weatherford International plc (NASDAQ:WFRD), reducing the price target to $69.00 from $73.00. The analyst stuck to a Buy rating due to the company’s future growth potential. He opined that while Weatherford International plc (NASDAQ:WFRD) is facing challenges such as asset divestitures and weaker market conditions, it has demonstrated resilience by focusing on maintaining a strong balance sheet, free cash flow conversion, and shareholder returns. These strategic priorities support the company’s favorable market standing in the face of downturns, positioning it in the fifth spot on our list of oversold NASDAQ stocks to buy right now.
The analyst further said that Weatherford International plc (NASDAQ:WFRD) surpassed expectations with its latest financial performance, with revenues exceeding its guidance’s midpoint and adjusted EBITDA following closely behind. Its initiatives to streamline its operations, such as the sale of some businesses, have slashed capital intensity and brought in significant proceeds, supporting the Buy rating.
4. Core Scientific, Inc. (NASDAQ:CORZ)
Perf YTD: -41.35%
Analyst Upside: 124.51%
Number of Hedge Fund Holders: 66
Core Scientific, Inc. (NASDAQ:CORZ) operates digital Bitcoin mining and high-performance computing infrastructure. The company leverages its own fleet of computers, called miners, to earn Bitcoin for its own account and also provides hosting services for Bitcoin mining and high-performance computing customers at eight US-based operational data centers.
On April 23, analyst Jonathan Petersen of Jefferies maintained a Buy rating on Core Scientific, Inc. (NASDAQ:CORZ) and reduced its price target to $14.00. The analyst supported his buy rating with the company’s growth potential and strategic positioning, believing it is uniquely positioned to capitalize on the exponentially growing data center demand. This holds especially true for those supporting AI infrastructure, thanks to the company’s expertise in the field, which is essential for securing partnerships with hyperscalers who are generally cautious about their vendor list expansion.
The analyst further reasoned that Core Scientific, Inc.’s (NASDAQ:CORZ) partnership with cloud provider CoreWeave to significantly expand its AI business is a key revenue growth driver, as the deal is anticipated to bring in around $851 million per annum after the utilization of capital expenditure credits. Peterson said that the market appears to be undervaluing this deal and potential deals with other hyperscalers in the future, pointing towards a misalignment in current stock pricing. Core Scientific, Inc. (NASDAQ:CORZ) is also expanding into strategic locations such as Auburn, AL, and has the potential to grow its power capacity. These factors further support the buy rating by positioning the company to meet the growing demand for data center space.
3. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Perf YTD: -43.72%
Analyst Upside: 131.07%
Number of Hedge Fund Holders: 44
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH). It ranks third on our list of the oversold NASDAQ stocks to buy now.
On April 25, William Blair analyst Lachlan Hanbury Brown maintained their bullish stance on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), giving a Buy rating on April 20 because of its growth prospects and market dynamics. The analyst said that the recent label expansion for Izervay, which is associated with Apellis, is anticipated to result in a quick growth rebound after an initial revenue decline because of a complete response letter. The company’s management gave optimistic guidance for Izervay sales in the coming fiscal year, which reflects confidence in expansion and market recovery.
The analyst further opined that diagnosis and treatment rates for geographic atrophy are undergoing growth due to direct-to-consumer marketing efforts, which is expected to support market growth for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and prove beneficial to both Syfovre and Izervay. Although the company is experiencing some challenges, such as funding shortfalls affecting the anti-VEGF market, its overall outlook remains positive, supported by potential for revenue growth and significant market expansion.
2. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Perf YTD: -49.41%
Analyst Upside: 165.00%
Number of Hedge Fund Holders: 50
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities to treat rare diseases. The company has several approved products to treat Duchenne muscular dystrophy and is developing potential therapeutical candidates for more disorders, including neuromuscular and central nervous system-related disorders. Its pipeline comprises more than 40 programs at various discovery, pre-clinical, and clinical development stages.
On April 16, Yanan Zhu, an analyst from Wells Fargo, maintained a Buy rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) with an associated price target of $115.00. The analyst supported the Buy rating with several factors, including the company’s progress in its LGMD clinical programs. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is on track with its SRP-9003 program for LGMD2E/R4 and expects to report Phase 3 EMERGENE study data by mid-2025.
The analyst also highlighted the promising regulatory progress for SRP-9003, with a pre-BLA meeting confirming accelerated approval pathway eligibility. Sarepta Therapeutics, Inc.’s (NASDAQ:SRPT) plan to file a BLA in H2 2025 is hailed as a positive catalyst by the analyst, supporting the Buy rating. In addition, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has had reassuring interactions with the FDA about its SRP-9005 program, pointing towards a clear future path for its clinical trials.
1. Vaxcyte, Inc. (NASDAQ:PCVX)
Perf YTD: -59.81%
Analyst Upside: 311.10%
Number of Hedge Fund Holders: 50
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.
Needham analyst Joseph Stringer maintained a bullish stance on Vaxcyte, Inc. (NASDAQ:PCVX), giving it a Buy rating on April 1. The analyst said that the company’s recent VAX-24 Phase 2 infant study data has bolstered confidence in its success with encouraging results. The overall expectations around the VAX-31 Phase 2 infant program are also positive, pointing to further advancements in their vaccine development pipeline.
The analyst further reasoned that Vaxcyte, Inc. (NASDAQ:PCVX) is committed to expanding its product offerings, and the introduction of the VAX-XL program, which could potentially enhance its market position, corroborates that. These factors combined support a favorable outlook for the company’s performance.
Overall, PCVX ranks first among the oversold NASDAQ stocks to buy right now. While we acknowledge the potential of oversold NASDAQ stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than PCVX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
